2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2006
2005
2004
2003
2002
1998
1997
1992

Major Events

  • Pharmaceutical Administration Bureau (ISAF) of Macau has approved the new drug application of Ruxolitinib Cream
  • CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
  • Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China
  • As the First Prescription Issued, Innovative Drug Velphoro® has entered National Scale Clinical Application
  • Two Innovative Drugs:Highly Selective TYK2 Inhibitor CMS-D001 and GnRH Receptor Antagonist CMS-D002 are approved for Drug Clinical Trials
  • Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro®
  • Obtained Exclusive License of Two Regenerative Medical Aesthetic Products

Corporate Honors

Major Events

  • Joined Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in Southeast Asia
  • Diazepam Nasal Spray (VALTOCO) has issued its First Prescriptions
  • First Prescription of ILUMETRI (Tildrakizumab Injection) Has Been Issued
  • Innovative drugs VALTOCO (Diazepam Nasal Spray),ILUMETRI (Tildrakizumab Injection) and rare disease drug Tetrabenazine Tablets have been newly included in China’s National Reimbursement Drug List(NRDL), XinHuoSu (Recombinant Human Brain Natriuretic Peptide for Injection) has continued to be included in NRDL
  • Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China
  • New Drug Application of Methotrexate Iniection, Pre-filled Svringe (for RA) was accepted by China NMPA
  • First Prescription of Metoject (Methotrexate Pre-filled Injection) Has Been Issued.
  • Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
  • First Prescription of Ruxolitinib Cream for Vitiligo Announced Under Boao Super Hospital’s Early Access Program
  • The first “Diazepam Nasal Spray” Approved for Marketing in China
  • Obtained Exclusive License of a Regenerative Medical Aesthetic Product
  • An Innovative Drug ILUMETRI “Tildrakizumab Injection” Approved for Marketing in China
  • Ophthalmic Tetravalent Bispecific Antibody Product Being Granted an Approval for Drug Clinical Trial
  • Establishment of Joint Venture by Rxilient and Junshi Biosciences to Jointly Develop and Commercialize Toripalimab in Multiple Countries in Southeast Asia
  • New Drug Application of Methotrexate Injection(Psoriasis) Approved in China

Corporate Honors

  • Won the “2023 Cailian Press Zhiyuan Award – Pioneer in Corporate Governance”
  • Was Selected as the “Most Popular Southbound Stock Connect Company” of 2023 Annual Golden GuruClub Awards
  • Won the "Most Socially Responsible Listed Company Award" by Zhitong Finance
  • Selected into "Top 20 Chinese pharmaceutical Listed Companies in ESG Competitiveness"
  • Shenzhen Kangzhe Listed on the "Corporate Donation List in of 2022 Shenzhen Charitable Donation List"
  • Shenzhen Kangzhe Listed in “Shenzhen Top 500 Enterprises”
  • Gained the Exclusive License of Cidine, an Exclusive, Marketed Oral Gastrointestinal Prokinetic Agent in China
  • Received MSCI-ESG "AA" rating again, leading the industry globally
  • Included in the First “Sustainability Yearbook (China)” of S&P Global
  • Included in the “Hang Seng Innovative Drug Index”

Major Events

  • Gaining Exclusive License for Ruxolitinib Cream for the Treatment of Vitiligo and Atopic Dermatitis
  • Gaining Exclusive License for BMI Botulinum Toxin Product
  • Acquired 60% equity interest in Heling and obtained exclusive product rights of the dermatology-grade skincare products "Heling Soothing Series"
  • Initiated the Southeast Asia business; obtained exclusive product rights of Insulin Series Products in 11 Southeast Asian countries
  • Obtained exclusive product rights of EyeOP1 Glaucoma Treatment Device in Mainland China, 11 Southeast Asian countries and other regions, and acquired approximately 33.4% equity interest in Eye Tech Care
  • Acquired global assets of VEGF/ANG2 Tetravalent Bispecific Antibody

Corporate Honors

  • Selected for the “Top 25 Listed Pharmaceutical Companies” of “Top 100 Hong Kong Listed Companies” for the Third Consecutive Year
  • Won the Awards of “Listed Biopharma with the Most Growing Value” and “Overseas Listed Company with the Most Growing Value”.
  • Won “Best Information Disclosure Award” in China IR Annual Awards
  • Awarded “Best Hong Kong Stock Connect listing Company”
  • Selected as the “Annual Growth Value Awards” of 2022 Annual Golden Award
  • Selected into “TOP20 ESG Competitiveness of Chinese Pharmaceutical Listed Companies”
  • Shenzhen Kangzhe was once again listed in “Shenzhen Top 500 Enterprises”
  • Won the “Top 10 Best Corporate Governance Companies in 2022” by Cailianshe
  • Once again listed on “CSR Ranking of Pharmaceutical Enterprises” by Southern Weekly

Major Events

  • Initiated the model of strategic investment in Chinese Biotech; made equity investment in Trinomab and established a joint venture to develop 4 fully human antibody novel drugs
  • Initiated the model of innovative products customization and entrusted a CRO for customized development of 4 innovative medicines
  • New Drug Applications of Diazepam Nasal Spray, Tildrakizumab Solution for Injection, and Methotrexate Injection, Pre-filled Syringe (for psoriasis) were accepted by China NMPA
  • Obtained clinical trial notices of Desidustat Tablets, Methotrexate Injection, Pre-filled Syringe (for RA), and Methylthioninium Chloride Enteric-coated Sustained-release Tablets from China NMPA
  • CMS Skinhealth, the dermatology and medical aesthetic company, was officially established; acquired three dermatology and medical aesthetic specialty companies including Luqa Ventures, Carnation Medical Technology and Xuli Medical, and achieved collaboration with OVMEDI; acquired assets or products rights of a number of products including Aethoxysklerol, Vmonalisa HA filler, FUBA5200 Focused Ultrasound Body Contouring System and Omega VL Thread Carving Products in Mainland China and/or other countries or regions
  • The ophthalmology business has been independently operated

Corporate Honors

  • Won the "Best Pharmaceutical and Medical Company" from Golden Hong Kong Listed Companies
  • Recognized as the “Honored Company” and the top three of "Best ESG" by the Institutional Investors Magazine
  • MSCI-ESG rating maintained "AA" for two consecutive years, leading the industry globally
  • Listed in "CSR Ranking of Pharmaceutical Enterprises in 2020" by Southern Weekly
  • Awarded the "Most Socially Responsible Listed Company" of Jinqilin Awards held by Sina Finance
  • Selected for “Top 25 Listed Pharmaceutical Companies” of “Top 100 Hong Kong Listed Companies”
  • Shenzhen Kangzhe was selected for "Shenzhen Top 500 Enterprises" and “Top 100 Corporate Taxpayers in Nanshan District”

Major Events

  • Obtained clinical trial notices of Cyclosporine Eye Drops 0.09% and Tildrakizumab Solution for Injection from China NMPA
  • Invested in Gelesis, and acquired product rights of PLENITY, a weight management product, in Mainland China and/or other countries or regions
  • Acquired product rights of four innovative products including Desidustat Tablets, Methotrexate Injection(Pre-filled Syringe), BCG for Intravesical Instillation, and Methylthioninium Chloride Enteric-coated Sustained-release Tablets in Mainland China and/or other countries or regions
  • CMS Health, the cross-border e-commerce business entity for consumer healthcare products, was officially established

Corporate Honors

  • MSCI-ESG rating upgraded to "AA", reaching the global leading level
  • Won the "Best Pharmaceutical and Medical Company" award from Golden Hong Kong Listed Companies
  • Won the “Excellent Pharmaceutical Industry Award” of “Top 100 Hong Kong Listed Companies”
  • Shenzhen Kangzhe was awarded the "Shenzhen Top 500 Enterprises" and "Top 100 Corporate Taxpayers in Nanshan District"
  • Tibet Kangzhe was awarded the "Excellent Development and Opening up Enterprise Award in Lhasa Economic and Technological Development Zone”
  • Included in “CNI Nanshan 50 Index” and "Hang Seng Large-Mid Cap (Investable) Index"

Major Events

  • Obtained the clinical trial notice of Diazepam Nasal Spray from China NMPA
  • Acquired product rights of seven innovative products including Cyclosporine Eye Drops 0.09%, Tildrakizumab Solution for Injection and Paclitaxel Injection Concentrate for Suspension in Mainland China and/or other countries or regions
  • Acquired product rights of 11 generics (including a complex generic) in Mainland China and/or other countries or regions

Corporate Honors

  • Won the "Best Hong Kong Stock-Connect Company" from Golden Hong Kong Listed Companies
  • Honored with three awards including “2019 Top 10 Listed Companies with the Highest Investment Value in China Pharmaceutical Industry”, “Top 100 Innovative Pharmaceutical Enterprises in China” and “Benchmarking Enterprises in Pharmaceutical Industry at the 70th Anniversary of PRC Founding” at the China Healthcare Summit of Entrepreneurs, Scientists and Investors
  • Tibet Kangzhe was awarded the “Top 20 Private Enterprises of Tibet Autonomous Region”

Major Events

  • Invested in four overseas biotech companies including Neurelis, Acticor Biotech, Blueberry Therapeutics and VAXIMM, and acquired assets or product rights of four innovative products including Diazepam Nasal Spray, ACT017 (anti-platelet humanized monoclonal antibody), BB2603 (terbinafine-nano spray) and VXM01 (oral T-cell immune agonist) in Mainland China and/or other countries or regions
  • Acquired product rights of two innovative products including novel lead small molecule compounds CF101 and CF102 in Mainland China and/or other countries or regions
  • Acquired assets of PoNS (portable neuromodulation stimulator) in Mainland China and/or other countries or regions

Corporate Honors

  • Won the "Most Valuable Pharmaceutical Listing Company" from Golden Hong Kong Listed Companies for three consecutive years
  • Selected as “Most Attractive Hong Kong Stock-Connect Companies for Institutional Investors”
  • Recognized as the "Honored Company" by the Institutional Investors Magazine
  • Won the "Hong Kong Stock-Connect Company with the Most Substantial Growth Potential" award in Golden Wing Award held by Securities Times
  • Awarded the "Shenzhen's Most Potential Employer"

Major Events

  • Invested in Destiny Pharma, and acquired assets of XF-73 and other antibacterial product portfolio in Mainland China and/or other countries or regions
  • Continued to be the largest shareholder of Tibet Rhodiola Pharmaceutical with a total of 36.83% equity interest after completing the capital increase

Corporate Honors

  • Once again won the BIVA “Best Investment Value Award for Listed Companies”
  • Once again won the "Most Valuable Pharmaceutical Listing Company" from Golden Hong Kong Listed Companies
  • Recognized as the “All-Asia Most Honored Company”by the Institutional Investors Magazine
  • Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Major Events

  • Obtained the exclusive right to commercialize Plendil in Mainland China

Corporate Honors

  • Won the BIVA “Best Investment Value Award for Listed Companies”
  • Won the "Most Valuable Pharmaceutical Listing Company" from Golden Hong Kong Listed Companies
  • Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” and “Top Ten Health Innovation Enterprises” by M.D. Weekly

Major Events

  • Acquired Xili Pharmaceutical and obtained the exclusive sale and marketing rights of DanShenTong in Mainland China
  • Acquired assets of Hirudoid and Combizym in Mainland China and/or other countries or regions

Corporate Honors

  • Ranked in the list of Forbes on the “Best Enterprises Under a Billion”
  • Awarded the “Best Listed Company” by Ta Kung Pao
  • Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”
  • Tianjing Kangzhe was awarded the “Top 20 Science and Technology Small Giant Enterprise Certificate (Tianjin Development Zone)” for two consecutive years and “Top 100 Enterprises in Tianjing Development Zone”

Major Events

  • Became the largest shareholder of Tibet Rhodiola Pharmaceutical with a total of 26.61% equity interest
  • Acquired assets of Augentropfen Stulln Mono Eye-drops, MOVICOL® and Parlodel® in Mainland China and/or other countries or regions

Corporate Honors

  • Included in the Morgan Stanley Capital International (MSCI) China Index
  • Ranked in the list of Forbes on ”Asia’s Best 200 Enterprises Under a Billion”
  • Won “The Listed Company with the Best Information Disclosure” of the “China Securities Golden Bauhinia Award” held by Ta Kung Pao
  • Tianjing Kangzhe was awarded the “Top 20 Science and Technology Small Giant Enterprise Certificate (Tianjin Development Zone)”
  • Shenzhen Kangzhe was awarded the “Top 100 Enterprises in Shenzhen”

Major Events

Corporate Honors

  • Shenzhen Kangzhe was awarded the “Top 100 Enterprises in Shenzhen”

Major Events

Corporate Honors

  • Ranked in the list of Forbes on “China's Best Up-And-Coming Businesses” for three consecutive years
  • Tianjin Kangzhe was recognized as “Tianjin High-tech Enterprise” and awarded the Certificate of “Tianjin A-grade Corporate Taxpayer”

Major Events

  • Acquired 100% equity interest of Tianjin Precede Medical Trade Development Co., Ltd. (renamed as Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd. In October 2011)

Corporate Honors

  • Ranked in the list of Forbes on “China's Best Up-And-Coming Businesses” for two consecutive years
  • Shenzhen Kangzhe was awarded the “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Major Events

  • Listed on the Main Board of the Stock Exchange of Hong Kong (Stock Code: 867)
  • Obtained the exclusive rights to promote and sell Bioflor in Mainland China

Corporate Honors

  • Ranked in the list of Forbes on “China's Best Up-And-Coming Businesses”
  • Shenzhen Kangzhe was awarded the “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Major Events

Corporate Honors

  • Shenzhen Kangzhe was awarded the “Top 100 Enterprises in Shenzhen”, “Top 100 Small and Medium Sized Innovative Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Major Events

  • Obtained the exclusive rights to promote and sell XinHuoSu, Cystistat and Salofalk in Mainland China

Corporate Honors

  • Ranked in the list of Forbes on “Asia’s Best 200 Enterprises Under a Billion”
  • Shenzhen Kangzhe was selected as "Leading Enterprises of Independent Innovation" and awarded the “Top 100 Corporate Taxpayers in Nanshan District”

Major Events

  • Obtained the exclusive rights to promote and sell Augentropfen Stulln Mono Eye-drops and GanFuLe in Mainland China

Corporate Honors

  • Shenzhen Kangzhe was awarded the “Top 100 Corporate Taxpayers” of Futian District

Major Events

Corporate Honors

  • Shenzhen Kangzhe was awarded the “Top 100 Corporate Taxpayers” of Futian District

Major Events

Corporate Honors

  • Shenzhen Kangzhe was awarded the “Top 50 Private Enterprise of Shenzhen”, “Top 100 Corporate Taxpayers” and “Top 100 Private Enterprise” of Futian District

Major Events

Corporate Honors

  • Shenzhen Kangzhe was awarded the “Top 100 Corporate Taxpayers” and “Top 100 Private Enterprise” of Futian district

Major Events

  • Obtained the exclusive rights to promote and sell Deanxit and Ursofalk in Mainland China

Corporate Honors

  • Shenzhen Kangzhe was awarded the “Top 100 Corporate Taxpayers” and “Top 100 Private Enterprise” of Futian district

Major Events

  • Affiliated company obtained the exclusive rights to promote and sell Ursofalk in Mainland China

Corporate Honors

Major Events

  • Affiliated company obtained the exclusive rights to promote and sell Deanxit in Mainland China

Corporate Honors

Major Events

  • CMS was Established

Corporate Honors